ArticleNature communications2021
The genome-wide impact of trisomy 21 on DNA methylation and its implications for hematopoiesis.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 59 citations in OpenAlex.
- Metabolomic Profiles in Down Syndrome: A Scoping Review of Convergent and Context-Dependent Patterns.Journal of intellectual disability research : JIDR · 2026Article
- RegRegSEA: a web server for regulatory region set enrichment analysis of epigenomic data.Nucleic acids research · 2026Article
- Aberrant chromatin remodeling influences human neural cell fate change in Trisomy 21.bioRxiv : the preprint server for biology · 2026Article
- A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms.Signal transduction and targeted therapy · 2026Article
- Systematic multi-omic deconvolution of the clinical heterogeneity of Down syndrome.Nature communications · 2026Article
- Epigenetic Control of Hyperuricemia and Gout by Gene Writer DNMT1 and RNA Editor ADAR1: Mechanism of Gout and Amyloid Dissolution in Down Syndrome.Biochemical genetics · 2026Article
- Increased methylation levels of theEpigenomics · 2025Article
- Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome.Blood advances · 2025Article
- Single-cell transcriptomics reveal individual and cooperative effects of trisomy 21 and GATA1s on hematopoiesis.Stem cell reports · 2025Article
- Identification of genetic and non-genetic modifiers of genomic imprinting through screening of imprinted DMR methylation in humans.Epigenetics & chromatin · 2025Article
- Super-enhancer DNA methylation in cancer: the mechanism of action and therapeutic directions.Frontiers in oncology · 2025Review
- Carcinogenesis trajectories.Frontiers in cell and developmental biology · 2025Article
- Anaesthesia for the child with trisomy 21.BJA education · 2024Review
- Article
- The effect of trisomic chromosomes on spatial genome organization and global transcription in embryonic stem cells.Cell proliferation · 2024Article
- The lncRNA Snhg11, a new candidate contributing to neurogenesis, plasticity, and memory deficits in Down syndrome.Molecular psychiatry · 2024Article
- A single-cell transcriptome atlas of human euploid and aneuploid blastocysts.Nature genetics · 2024Article
- Gene Expression Studies in Down Syndrome: What Do They Tell Us about Disease Phenotypes?International journal of molecular sciences · 2024Review
- Down syndrome-associated leukaemias: current evidence and challenges.Therapeutic advances in hematology · 2024Review
- GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development.Advances in experimental medicine and biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Ivo S MuskensCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Shaobo Li *Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-0544-5338
Thomas Jackson *Department of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford, UK.
Natalina Elliot *Department of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford, UK.
Helen M HansenDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Swe Swe MyintCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Priyatama PandeyCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Jeremy M SchrawDepartment of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA.
Ritu RoyComputational Biology and Informatics, University of California San Francisco, San Francisco, CA, USA.
Joaquin AnguianoDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Katerina GoudevenouDepartment of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford, UK.
Kimberly D SiegmundDepartment of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.ORCID 0000-0001-7599-9726
Philip J LupoDepartment of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA.
Marella F T R de BruijnMRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-4934-4125
Kyle M WalshDepartment of Neurosurgery, Duke University, Durham, NC, USA.ORCID 0000-0002-5879-9981
Paresh VyasMRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID 0000-0003-3931-0914
Xiaomei MaDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Anindita RoyDepartment of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford, UK.ORCID 0000-0001-8607-5748
Irene RobertsDepartment of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford, UK.
Joseph L WiemelsCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Adam J de SmithCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. adam.desmith@med.usc.edu.ORCID 0000-0003-4880-7543
University of Oxford · GBUniversity of Southern California · USUniversity of California, San Francisco · USBaylor College of Medicine · USDuke University · USYale University · US
Funding
Molecular epidemiology of acute lymphoblastic leukemia in children with Down syndromeR01CA249867 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LUPO, PHILIP, RABIN, KAREN R · 2020 to 2024
$4.2MPerinatal immune development and risk of childhood acute lymphoblastic leukemiaR01CA175737 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MA, XIAOMEI, WIEMELS, JOSEPH LEO · 2014 to 2018
$3.0MDepartment of HealthMedical Research Council G1000729Medical Research Council MC_U137961146Medical Research Council MC_UU_00016/11Medical Research Council MC_UU_00016/13Medical Research Council MC_UU_00016/2Medical Research Council MC_UU_12009/11Medical Research Council MR/L008963/1Medical Research Council MR/R006237/1NCI NIH HHS R01 CA175737NCI NIH HHS R01 CA249867Wellcome TrustWellcome Trust 099175/Z/12/ZWellcome Trust 216632/Z/19/Z
Abstract
Down syndrome is associated with genome-wide perturbation of gene expression, which may be mediated by epigenetic changes. We perform an epigenome-wide association study on neonatal bloodspots comparing 196 newborns with Down syndrome and 439 newborns without Down syndrome, adjusting for cell-type heterogeneity, which identifies 652 epigenome-wide significant CpGs (P < 7.67 × 10
Indexed as
Epigenesis, GeneticCase-Control StudiesCore Binding Factor Alpha 2 SubunitCpG IslandsDNA MethylationDown SyndromeFemaleFetusGATA1 Transcription FactorGenome, HumanGenome-Wide Association StudyHematopoiesisHematopoietic Stem CellsHumansInfant, NewbornLiverCore Binding Factor Alpha 2 SubunitFLI1 protein, humanGATA1 protein, humanGATA1 Transcription FactorProto-Oncogene Protein c-fli-1RUNX1 protein, human
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.